Atipharmed.com Website Review

the first multinational pharmaceutical company focused on women. atipharmed is a multinational pharmaceutical company founded in iran in 2011.the company is the first modular gmp licensed pharmaceutical company that focused on female se* hormones production in iran. as a tech-transfer and safety-oriented pharmaceutical company, atipharmed is committed to create the best solutions to empower women’s life at every stage through european joint-venture technology transfer. cybelle an antiandrogenic contraceptive medicine is made up of cyproterone acetate 2mg + ethinyl estradiol .035mg each blister includes 21 effective tablets and 7 placebo tablets. cybelle is being produced for the first time under the license of chemo company in the levitude is a combined oral contraceptive that consists of a progesterone called levonorgestrel and an estrogenic component called ethinyl estradiol. the drug is a second-generation contraceptive pill. levitude is being produced for the first time under the license of chemo company in the atipharmed international pharmacy company of iran. tansy an emergency contraception is made up of a synthetic progesterone called levonorgestrel (1.5 mg levonorgestrel containing one tablet and 0.75 mg levonorgestrel containing two tablets). tansy is being produced for the first time under the license of chemo company in the atipharmed international pharmacy company of iran. drosbelin is a combined oral contraceptive which its progesteronic component called drospirenone and estrogenic component called ethinylestradiol. drosbelin is a fourth-generation contraceptive pill. drosbelin is being produced for the first time under the license of drosbela is a combined oral contraceptive which its progesteronic component called drospirenone and estrogenic component called ethinylestradiol. drosbela is a fourth-generation contraceptive pill. drosbela is being produced for the first time under the license of. atipharmed is a multinational pharmaceutical company founded in iran in 2011.